Taiwanese biopharmaceutical company Golden Biotechnology Corp. on Wednesday released positive interim unblinded data from the Phase 2 clinical trial of its oral investigational new drug for COVID-19 Antroquinonol, and announced it plans to apply for Emergency Use Authorization (EUA) in the United States in April.
(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)
Latest
- Business
CAL to partner with Southwest Airlines to expand North America network
06/02/2025 05:31 PM - Business
AirAsia to launch Taipei-Fukuoka route on Aug. 15
06/02/2025 05:16 PM - Society
'Cool map' not enough in summer heat; more plants needed: Expert
06/02/2025 04:27 PM - Business
U.S. dollar closes higher on Taipei forex
06/02/2025 04:13 PM - Business
Taiwan shares sharply lower amid deeper concerns over U.S. tariff policies
06/02/2025 04:08 PM